Keros Therapeutics — Technical Presentation (December 2020)

5 slides from Keros Therapeutics's technical presentation, Dec 7, 2020

Slide 1: MAD: Average Change from Baseline in Transferrin Saturation Through Day 7
MAD: Average Change from Baseline in Transferrin Saturation Through Day 7
Slide 2: MAD: Average Change from Baseline in Ferritin Through Day 7
MAD: Average Change from Baseline in Ferritin Through Day 7
Slide 3: MAD: Hepcidin Percent Change from Baseline at Day 7, 8 hrs Post-Dose
MAD: Hepcidin Percent Change from Baseline at Day 7, 8 hrs Post-Dose
Slide 4: Mean Reticulocyte Hemoglobin at each visit
Mean Reticulocyte Hemoglobin at each visit
Slide 5: Multiple Modalities of ALK2 Inhibition Reduced Hepcidin and Resolved Anemia in IRIDA Model
Multiple Modalities of ALK2 Inhibition Reduced Hepcidin and Resolved Anemia in IRIDA Model • Selective Inhibition of ALK2 Signaling Suppresses Serum Hepcidin and Increases Serum Iron – Publication Number : 771 In an siRNA-based model of iron-refractory iron deficiency anemia (“IRIDA”), administratio